Jacob Bell
New Member
Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol
Author(s) Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA
Institution New York State Psychiatric Institute, Division on Substance Abuse, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. frl2@columbia.edu
Source Drug Alcohol Depend 2010 Jan 1; 106(1):65-8.
MeSH Adult
Double-Blind Method
Female
Hallucinogens
Humans
Male
Marijuana Smoking
Middle Aged
Socioeconomic Factors
Substance Abuse Detection
Tetrahydrocannabinol
Abstract The purpose of this study was to determine whether Delta(9)-tetrahydrocannabivarin (THCV), a plant cannabinoid, is a sensitive measure to detect recent marijuana use in cannabis dependent patients. It has been purported that smoking an illicit plant cannabis product will result in a positive THCV urinalysis, whereas the oral ingestion of therapeutic THC such as dronabinol will result in a negative THCV urinalysis, allowing for discrimination between pharmaceutical THC products and illicit marijuana products. In a double-blind placebo-controlled trial to determine the efficacy of dronabinol in cannabis dependence, all 117 patients produced a positive urine for the marijuana metabolite 11-nor-Delta(9)-THC-9-carboxylic acid; THC-COOH, but 50% had an undetectable (<1 ng/ml) THCV-COOH test. This suggests that THCV may not be a sensitive enough measure to detect recent marijuana use in all heavy marijuana users or that its absence may not discriminate between illicit marijuana use and oral ingestion of THC products such as dronabinol. We propose that the lack of THCV detection may be due to the variability of available cannabis strains smoked by marijuana users in community settings.
Language eng
Pub Type(s) Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
PubMed ID 19733018
Source: Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol
Author(s) Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA
Institution New York State Psychiatric Institute, Division on Substance Abuse, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. frl2@columbia.edu
Source Drug Alcohol Depend 2010 Jan 1; 106(1):65-8.
MeSH Adult
Double-Blind Method
Female
Hallucinogens
Humans
Male
Marijuana Smoking
Middle Aged
Socioeconomic Factors
Substance Abuse Detection
Tetrahydrocannabinol
Abstract The purpose of this study was to determine whether Delta(9)-tetrahydrocannabivarin (THCV), a plant cannabinoid, is a sensitive measure to detect recent marijuana use in cannabis dependent patients. It has been purported that smoking an illicit plant cannabis product will result in a positive THCV urinalysis, whereas the oral ingestion of therapeutic THC such as dronabinol will result in a negative THCV urinalysis, allowing for discrimination between pharmaceutical THC products and illicit marijuana products. In a double-blind placebo-controlled trial to determine the efficacy of dronabinol in cannabis dependence, all 117 patients produced a positive urine for the marijuana metabolite 11-nor-Delta(9)-THC-9-carboxylic acid; THC-COOH, but 50% had an undetectable (<1 ng/ml) THCV-COOH test. This suggests that THCV may not be a sensitive enough measure to detect recent marijuana use in all heavy marijuana users or that its absence may not discriminate between illicit marijuana use and oral ingestion of THC products such as dronabinol. We propose that the lack of THCV detection may be due to the variability of available cannabis strains smoked by marijuana users in community settings.
Language eng
Pub Type(s) Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
PubMed ID 19733018
Source: Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol
